Universitätsklinikum Würzburg

A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients (2019) Hammer F, Malzahn U, Donhauser J, Betz C, Schneider M, Grupp C, Pollak N, et al. Journal article Human NK cells adapt their immune response towards increasing multiplicities of infection of Aspergillus fumigatus (2018) Marischen L, Englert A, Schmitt AL, Einsele H, Loeffler J Journal article Cellular therapy with engineered T cells, efficacy and side effects (2018) Bondanza A, Bonini C, Fehse B, Hudecek M Authored book Validation of a simplified in vitro Transwell® model of the alveolar surface to assess host immunity induced by different morphotypes of Aspergillus fumigatus (2018) Morton CO, Wurster S, Fliesser M, Ebel F, Page L, Huenniger K, Kurzai O, et al. Journal article Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure (2018) Page L, Weis P, Mueller T, Dittrich M, Lazariotou M, Dragon M, Waaga-Gasser AM, et al. Journal article Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) Went M, Sud A, Forsti A, Halvarsson BM, Weinhold N, Kimber S, Van Duin M, et al. Journal article Immunomodulation as a therapy for Aspergillus infection: Current status and future perspectives (2018) Lauruschkat CD, Einsele H, Loeffler J Journal article, Review article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution